Session (CTI)

Despite the considerable effort to improve patient centricity in oncology, effective scientific evaluation of the treatment experience through patient-reported outcomes (PROs) continues to be challenging given the differential implementation needs across multiple stakeholders (e.g., patients, physicians, industry, HTA bodies). While there is significant interest in improving PRO measurements given the clear benefit to patient care, efforts do not include the multistakeholder perspective and the optimal path forward remains unclear. PRO measures (PROMs) have become a fundamental component of clinical oncology. Well-established historical PROMs are included in clinical studies for regulatory evaluation and market access; however, they may not fully capture the patient experience and inclusion of several PROMs may impact compliance. While PROMs are being incorporated into clinical practice to increase patient centricity, the optimal instruments from a health-system perspective may increase physician burden without allowing accurate characterization of the patient experience. Patients are also looking to PROMs to improve their care journey in real-time but are highlighting the need to evolve past historical measures to novel PROMs, which may not be fully validated from a methodological standpoint. Accordingly, the evolution of PROMs is currently limited by differing value perspectives of key stakeholders, which will need to be resolved to advance patient-centric care. Dr. Kristi Bertzos will spend 10 minutes presenting the industry perspective on inclusion of PROMs in clinical studies. Abeer Al-Rabayah will spend 10 minutes discussing the incorporation of PROs in clinical practice in the Middle East and North Africa. Eva Villalba will spend 10 minutes on the patient perspective of how to better capture PROs. Presentations will be followed by discussion and audience engagement.